Antimicrobial Efficacy of Cathelicidin Peptides on Multidrug-Resistant Pseudomonas aeruginosa Strains

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F24%3A00139965" target="_blank" >RIV/00216224:14110/24:00139965 - isvavai.cz</a>

Result on the web

—

DOI - Digital Object Identifier

—

Result language

angličtina

Original language name

Antimicrobial Efficacy of Cathelicidin Peptides on Multidrug-Resistant Pseudomonas aeruginosa Strains

Original language description

Background and Aims Multidrug-resistant (MDR) Pseudomonas aeruginosa strains are resistant to nearly all antibiotics, including carbapenems and cause many types of healthcare-associated infections. Cathelicidins are small cationic, amphiphilic peptides that exhibit broad-spectrum activity against bacteria, fungi, and viruses. Methods MDR P. aeruginosa strains (n = 19) isolated from clinical samples were used to assess the antimicrobial effect of five cathelicidins and their combinations (LL-37, PMAP-23, SMAP-29, protegrin-1 and chicken CATH-2). An antimicrobial inhibition test was performed to evaluate minimal inhibition and bactericidal concentrations (MIC90 and MBC) for both planktonic forms of bacteria and biofilm. MIC90 was defined as a 10-fold decrease, and MBC as a 1000-fold decrease in bacterial numbers. Results SMAP-29, protegrin-1, and CATH-2 peptides showed bactericidal effect on all tested strains, LL-37 on 89,5 % of strains and PMAP-23 on 84 %. The most substantial synergistic effects were recorded in the following combinations: LL-37/SMAP-29, LL-37/protegrin-1, LL-37/CATH-2, SMAP-29/protegrin-1, PMAP-23/protegrin-1, PMAP-23/CATH-2. The peptide concentrations needed to observe the MIC90 antimicrobial effect in these combinations were up to 10-fold lower than when used individually. This effect was also noted when used for biofilm treatment. Conclusions All studied cathelicidin peptides showed antimicrobial activity against MDR P. aeruginosa strains. The potential cytotoxicity of antimicrobial peptides at higher concentrations hinders their therapeutic use. An appropriate combination of peptides allows for the reduction of the quantity of administered peptides, thus increasing their suitability for practical clinical use. This study was supported by the Ministry of Health of the Czech Republic, grant nr. NU22-05-00475. All rights reserved.

Czech name

—

Czech description

—

Type

O - Miscellaneous

CEP classification

—

OECD FORD branch

10606 - Microbiology

Project

<a href="/en/project/NU22-05-00475" target="_blank" >NU22-05-00475: Treatment of Infections Caused by Multidrug-Resistant Bacterial Strains by Novel Antibacterial Preparations Based on Cathelicidin Antimicrobial Peptides</a><br>

Continuities

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year

2024

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů